Clinical trial Recruiting at 1 site Observational Ages 18 to 75

Measuring urine S1P to detect overactive bladder in people with multiple sclerosis

Official title: Prospective Study Evaluating the Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis

Run by University Hospital, Toulouse · NCT06161376 · Data updated 2026-11-12

We will test whether measuring a urine molecule called sphingosine 1-phosphate (S1P) can indicate bladder overactivity in people with multiple sclerosis who are undergoing urodynamic testing.

Quick facts

Study typeObservational
Ages18 Years to 75 Years
SexAll
Enrollment400 (estimated)
SponsorUniversity Hospital, Toulouse
Academic / other
Locations1 site (Toulouse)
StatusRecruiting
StartedDecember 4, 2023
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedDecember 31, 2025
Trial IDNCT06161376 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are French residents with multiple sclerosis who are enrolled in the social security system and are scheduled for urodynamic testing without active urinary infection or exclusionary pelvic/bladder conditions.

Probably not a fit

Patients with anatomical subvesical obstruction, urothelial carcinoma, interstitial cystitis, prior augmentation cystoplasty, untreated urinary tract infection, or those not undergoing urodynamic testing are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will measure urinary S1P levels in French patients with multiple sclerosis who are scheduled for urodynamic evaluation at Toulouse University Hospital. Urine samples will be collected and analyzed for S1P and compared with simultaneous urodynamic measurements of detrusor activity. Patients with active urinary tract infection, pregnancy, legal guardianship restrictions, or specific pelvic/bladder conditions are excluded. The aim is to confirm whether urinary S1P correlates with invasive urodynamic findings and could serve as a noninvasive biomarker.

Why it matters

Potential benefit: If successful, a urine S1P test could provide a noninvasive way to detect detrusor overactivity and reduce reliance on invasive urodynamic testing.

How similar studies have gone: Preliminary work at Toulouse University Hospital suggests a link between urinary S1P and detrusor activity, but this biomarker has not yet been validated in larger or multicenter cohorts.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* French residents enrolled in the social security system
* Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not
* Patients scheduled for urodynamic assessment as part of their management

Exclusion criteria:

* Pregnant or lactating females
* Patients under legal guardianship
* Untreated urinary tract infection at the time of inclusion
* Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty

Where it's running

  • Toulouse Hospital
    Toulouse, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.